Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 40 g/l - injection, solution - excipient ingredients: chloride; water for injections; sodium; octanoate - indications as at 27 january 2000 : hypovolaemia/shock: preservation of an adequate circulating blood volume should be the primary aim of therapy. the initial resuscitating fluid should not be a human blood product, but rather an alternative plasma volume expander should be used as a first-line replacement. albumex 4 may, however, be the initial plasma expander of choice if shock is associated with significant hypoalbuminaemia (albumin concentration less than 25g/litre), or if it is clinically desirable to avoid the infusion of large volumes of crystalloid solutions. albumex 4 may also be useful following initial resuscitation with crystalloid or synthetic colloid solutions in patients in whom extended support of the intravascular volume is required, such as seriously ill patients with multiple organ failure or the systemic capillary leak syndrome. cardiopulmonary bypass: albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery for patients with poor left ventricular function, and other complicating factors such as long bypass time, anaemia or repeat surgery. for post-operative hypovolaemia albumex 4 may be used if further colloid is required after a moderate amount of synthetic colloid (1-2l) has been given, or there is ongoing bleeding or anaemia, until cross-matched blood is available. plasma exchange: albumex 4 is indicated as a replacement solution in plasma exchange procedures, particularly when the volume exchanged exceeds 20ml/kg body weight. in patients with thrombotic thrombocytopenic purpura, fresh frozen plasma may be a preferred replacement.,albumex 4 is a plasma volume expander for restoration and maintenance of circulating blood volume. albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery. albumex 4 is indicated as a replacement solution in plasma exchange procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 40 g/l - injection, solution - excipient ingredients: water for injections; sodium; chloride; octanoate - indications as at 27 january 2000: hypovolaemia/shock: preservation of an adequate circulating blood volume should be the primary aim of therapy. the initital resuscitating fluid should not be a human blood product, but rather an alternative plasma volume expander should be used as a first-line replacement. albumex 4 may, however, be the initial plasma expander of choice if shock is associated with significant hypoalbuminaemia (albumin concentration less than 25g/litre), or it is clinically desirable to avoid the infusion of large volumes of crystalloid solutions. albumex 4 may also be useful following initital resuscitation with crystalloid or synthetic colloid solutions in patients in whom extended support of the intravascular volume is required, such as seriously ill patients with multiple organ failure or the systemic capillary leak syndrome. cardiopulmonary bypass: albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery for patients with poor left ventricular function, and other complicating factors such as long bypass time, anaemia or repeat surgery. for post-operative hypovolaemia albumex 4 may be used if further colloid is required after a moderate amount of synthetic colloid (1-2l) has been given, or there is ongoing bleeding or anaemia, until cross-matched blood is available. plasma exchange: albumex 4 is indicated as a replacement solution in plasma exchange procedures, particularly when the volume exchanged exceeds 20ml/kg body weight. in patients with thrombotic thrombocytopenic purpura, fresh frozen plasma may be preferred replacement.,albumex 4 is a plasma volume expander for restoration and maintenance of circulating blood volume. albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery. albumex 4 is indicated as a replacement solution in plasma exchange procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 0.2 g/ml - injection, intravenous infusion - excipient ingredients: octanoate; sodium; water for injections - indications as at 27 january 2000: hypoproteinaemia in the acutely ill patient: albumex 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. shock: albumex 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 4-5% human albumin is preferred when available. burns: extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins, resulting in hypovolaemic shock and circulatory failure. inititally (during the first 24 hours) there is an increased vascular permeability leading to loss of water and proteins into the extravascular compartment, and haemoconcentration. large volumes of crystalloid solutions should be infused to restore the constricted intravascular fluid space, and smaller amounts of albumex 20 are required to maintain adequate plasma volume and colloid osmotic pressure. adult respiratory distress syndrome

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 0.2 g/ml - injection, intravenous infusion - excipient ingredients: water for injections; sodium; octanoate - indications as at 27 january 2000: hypoproteinaemia in the acutely ill patient: albumex 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. shock: albumex 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 4-5% human albumin is preferred when available. burns: extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins, resulting in hypovolaemic shock and circulatory failure. inititally (during the first 24 hours) there is an increased vascular permeability leading to loss of water and proteins into the extravascular compartment, and haemoconcentration. large volumes of crystalloid solutions should be infused to restore the constricted intravascular fluid space, and smaller amounts of albumex 20 are required to maintain adequate plasma volume and colloid osmotic pressure. adult respiratory distress syndrome

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 40 g/l - injection, solution - excipient ingredients: chloride; octanoate; water for injections; sodium - indications as at 27 january 2000 :hypovolaemia/shock: preservation of an adequate cirulating blood volume should be the primary aim of therapy. the initial resuscitating fluid should not be a human blood product, but rather an alternative plasma volume expander should be used as a first-line replacement. albumex 4 may, however, be the initial plasma expander of choice if shock is associated with significant hypoalbuminaemia (albumin concentration less than 25g/litre) or if it is clinically desirable to avoid the infusion of large volumes of crystalloid solutions. albumex 4 may also be useful following initial resuscitation with crystalloid or synthetic colloid solutions in patients in whom extended support of the intravascular volume is required, such as seriously ill patients with multiple organ failure or the systemic capillary leak syndrome. cardiopulmonary bypass: albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery for patients with poor left ventricular function, and other complicating factors such as long bypass time, aneamia or repeat surgery. for post-operative hypovolaemia albumex 4 may be used if further colloid is required after a moderate amount of synthetic colloid (1-2l) has been given, or there is ongoing bleeding or anaemia, until cross-matched blood is available. plasma exchange: albumex 4 is indicated as a replacement solution in plasma exchange procedures, particularly when the volume exchanged exceeds 20ml/kg body weight. in patients with thrombotic thrombocytopenic purpura, fresh frozen plasma may be preferred replacement.,albumex 4 is a plasma volume expander for restoration and maintenance of circulating blood volume. albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery. albumex 4 is indicated as a replacement solution in plasma exchange procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

juniper biologics pty ltd - palonosetron hydrochloride, quantity: 56 microgram/ml (equivalent: palonosetron, qty 50 microgram/ml) - injection, solution - excipient ingredients: sodium hydroxide; disodium edetate; hydrochloric acid; sodium citrate dihydrate; mannitol; water for injections; citric acid monohydrate - aloxi is indicated for: - prevention of nausea and vomiting induced by cytotoxic chemotherapy. - prevention of postoperative nausea and vomiting (ponv) for up to 24 hours following surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - acetylcysteine, quantity: 2 g - injection, concentrated - excipient ingredients: disodium edetate; water for injections; sodium hydroxide - antidote for paracetamol poisoning. ,acetylcysteine is indicated in the treatment of paracetamol overdose to protect against hepatotoxity.

Australia - English - Department of Health (Therapeutic Goods Administration)

juniper biologics pty ltd - palonosetron hydrochloride, quantity: 56 microgram/ml (equivalent: palonosetron, qty 50 microgram/ml) - injection, solution - excipient ingredients: sodium hydroxide; disodium edetate; hydrochloric acid; sodium citrate dihydrate; mannitol; water for injections; citric acid monohydrate - aloxi is indicated for: - prevention of nausea and vomiting induced by cytotoxic chemotherapy. - prevention of postoperative nausea and vomiting (ponv) for up to 24 hours following surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadobenate dimeglumine, quantity: 529 mg/ml - injection, solution - excipient ingredients: water for injections - multihance is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (mri) indicated for: for use in adults for the enhancement of magnetic resonance imaging (mri) of the liver and central nervous system (cns) for diagnostic use only. for use in adult patients with suspected or known vascular disease for contrast-enhanced magnetic resonance angiography of the abdominal or peripheral arteries where it improves the diagnostic accuracy for detecting clinically significant steno-occlusive vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadobenate dimeglumine, quantity: 529 mg/ml - injection, solution - excipient ingredients: water for injections - multihance is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (mri) indicated for: for use in adults for the enhancement of magnetic resonance imaging (mri) of the liver and central nervous system (cns) for diagnostic use only. for use in adult patients with suspected or known vascular disease for contrast-enhanced magnetic resonance angiography of the abdominal or peripheral arteries where it improves the diagnostic accuracy for detecting clinically significant steno-occlusive vascular disease.